

BEST AVAILABLE COPY


Amendment under 37 C.F.R. § 1.111
 USSN 10/069,007

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A ~~drug-cell death inhibitor~~ comprising, as an active ingredient, an indolylmalcimine derivative represented by the following formula (I):



(I)

wherein R¹ represents an unsubstituted alkyl group, unsubstituted alkenyl, ~~which may be substituted, an alkenyl group which may be substituted, an aryl group which may be substituted, hydroxyl group, an alkoxyl group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or hydrogen atom~~; R² represents a hydrogen atom, an unsubstituted alkyl group, unsubstituted alkenyl or unsubstituted alkynyl ~~which may be substituted, an alkenyl group which may be substituted, an alkynyl group which may be substituted, an aryl group which may be substituted, an acyl group which may be substituted, an alkoxy or aryloxy carbonyl group which may be substituted, an alkyl or arylthiocarbonyl group which may be substituted, an aminocarbonyl group which may be~~

Amendment under 37 C.F.R. § 1.111
 USSN 10/069,007

~~substituted, an alkyl- or arylsulfonyl group which may be substituted, an alkoxyl group which may be substituted, an aryloxy group which may be substituted, or hydroxyl group; R³ represents~~
 substituent(s) on an indole ring, and represents, number and position (2-, 4-, 5-, 6-, or 7-position
 as position number of the indole ring) of the substituent(s) and kinds of the substituent(s) may be
 the same or different, hydrogen, unsubstituted alkyl, unsubstituted alkenyl, or unsubstituted
alkynyl-atom, ~~an alkyl group which may be substituted, an alkenyl group which may be~~
~~substituted, an alkynyl group which may be substituted, an aryl group which may be substituted,~~
~~an acyl group which may be substituted, an alkoxy- or aryloxy carbonyl group which may be~~
~~substituted, an alkoxy- or aryloxy carbonyloxy group which may be substituted, an alkyl- or~~
~~arylthiocarbonyl group which may be substituted, an aminocarbonyl group which may be~~
~~substituted, an alkyl- or arylsulfonyl group which may be substituted, an alkoxyl group which~~
~~may be substituted, an aryloxy group which may be substituted, an alkyl- or arylthio group~~
~~which may be substituted, hydroxyl group, carboxyl group, cyano group, nitro group, an amino~~
~~group which may be substituted, or a halogen atom; R⁴ represents hydrogen atom, an alkyl group~~
~~which may be substituted, an alkenyl group which may be substituted, an alkynyl group which~~
~~may be substituted, an aryl group which may be substituted (except 3-indolyl group), an acyl~~
~~group which may be substituted, an alkoxy- or aryloxy carbonyl group which may be substituted,~~
 an alkyl- or arylthiocarbonyl group which may be substituted, an aminocarbonyl group which
 may be substituted, an alkyl- or arylsulfonyl group which may be substituted, an alkoxyl group
 which may be substituted, an aryloxy group which may be substituted, alkyl- or arylthio group
 which may be substituted, hydroxyl group, ~~carboxyl group, cyano group, nitro group, or amino~~

Amendment under 37 C.F.R. § 1.111
USSN 10/069,007

group which may be substituted; R^2 and R^3 , R^2 and R^4 , R^3 and R^4 may be combined to form a hydrocarbon chain which may be substituted; and in the formula, the bond accompanying a dotted line represents a double bond or a single bond, or a pharmaceutically acceptable salt thereof.

2. (currently amended) A drug for treating or preventing ~~progress of symptoms, through~~ ~~inhibiting~~ death of neurons associated with, of neurodegenerative diseases such as Alzheimer's disease, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, pigmentary degeneration of the retina, glaucoma and cerebellar degeneration, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

3. (currently amended) A drug for treating or preventing ~~progress of symptoms, through~~ ~~inhibiting~~ death of neurons associated with, of neonatal jaundice, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

4. (currently amended) A drug for treating or preventing ~~progress of symptoms, through~~ ~~inhibiting~~ cell death associated with, of myasthenia gravis, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Amendment under 37 C.F.R. § 1.111
USSN 10/069,007

5. (currently amended) A drug for treating or preventing ~~progress of symptoms, through~~ ~~inhibiting~~ death of neurons associated with, ~~of~~ brain ischemia and delayed neuronal death (DND), comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

6. (currently amended) A drug for treating or preventing ~~progress of symptoms, through~~ ~~inhibiting~~ death of myocardial cells associated with, ~~of~~ ischemic heart disease, viral myocarditis, ~~autoimmune myocarditis~~, myocardial disorders/cell death due to hypertrophic heart and heart failure, or arrhythmogenic right ventricular cardiomyopathy, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

7. (currently amended) A drug for treating or preventing ~~progress of symptoms, through~~ ~~inhibiting~~ death of hepatic cells associated with, ~~of~~ alcoholic hepatitis or viral hepatitis, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

8. (currently amended) A drug for treating or preventing ~~progress of symptoms, through~~ ~~inhibiting~~ death of renal cells associated with, ~~of~~ renal diseases, comprising a indolylmaleimide

Amendment under 37 C.F.R. § 1.111
USSN 10/069,007

derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

9. (currently amended) A drug for treating or preventing ~~progress of symptoms, through~~ ~~inhibiting~~ excessive death of T-cells associated with, ~~of~~ acquired immunodeficiency syndrome (AIDS), comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

10. (currently amended) A drug for treating or preventing ~~progress of symptoms,~~ ~~through inhibiting~~ cell death associated with, ~~of~~ inflammatory skin disorders, alopecia, or graft versus host disease (GVH), comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

11. (currently amended) A drug for treating or preventing ~~disorders or side effects,~~ ~~through inhibiting~~ cell death associated with, ~~of~~ disorders due to radiation or drugs, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

12. (currently amended) A drug for treating or preventing ~~progress of symptoms,~~ ~~through inhibiting~~ cell death associated with, ~~of~~ sepsis, comprising a indolylmaleimide derivative

Amendment under 37 C.F.R. § 1.111
USSN 10/069,007

represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

13. (currently amended) A drug for treating or preventing ~~progress of symptoms,~~
~~through inhibiting~~ death of cells derived from bone marrow, wherein said cell death is associated
with osteomyelo-dysplasia, comprising a indolylmaleimide derivative represented by the above
formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

14. (currently amended) A drug for treating or preventing ~~progress of symptoms,~~
~~through inhibiting~~ cell death associated with, of insulin dependent diabetes, comprising a
indolylmaleimide derivative represented by the above formula [II] or a pharmaceutically
acceptable salt thereof as an active ingredient.

15. (currently amended) A drug for treating or preventing ~~progress of symptoms,~~
~~through inhibiting~~ death of neurons associated with, of prion diseases, comprising a
indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically
acceptable salt thereof as an active ingredient.

16. (currently amended) A drug for treating or preventing cell death associated with
functional deficiency of transplanted organs, tissues or cells at transplantation of organs, tissues

Amendment under 37 C.F.R. § 1.111
USSN 10/069,007

or cells, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

17. (original) A preservative for organs, tissues or cells, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.